At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 23 enrolled
Drug / intervention
LY3185643 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, 9-Way, Single-Dose, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of LY3185643 and rGlucagon in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating LY3185643 and rGlucagon for Healthy. Completed, enrolled 23 participants across 1 site.
Detailed Summary
The purpose of this study is to determine how the body handles LY3185643 and rGlucagon and what effects LY3185643 and rGlucagon have on the body. This study will also help to determine if LY3185643 is safe and well-tolerated. This study will last at least 35 days, not including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartNov 2016
Primary CompletionJan 2017
Study CompletionMar 2017
TodayJul 2026
First PostedNov 1, 2016
Enrollment StartNov 1, 2016
Primary CompletionJan 24, 2017
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 9.7 years ago
Interventions
LY3185643drug
Administered SC
rGlucagondrug
Administered SC